Can You Take Naproxen with Amitriptyline?
A plain-English look at the moderate interaction between Naproxen (Pediapharm Naproxen Suspension 25 mg/mL (Medexus Pharma, Canada)) and Amitriptyline (ENTRIP) — what it means, why it happens, and what to talk to your doctor or pharmacist about.
Combining Naproxen (Pediapharm Naproxen Suspension 25 mg/mL (Medexus Pharma, Canada)) with Amitriptyline (ENTRIP) is a moderate interaction requiring caution and monitoring. Risk of serotonin syndrome, especially with tramadol and tapentadol combined with SSRIs/SNRIs. Additive CNS depression with sedating antidepressants.
Not sure about your specific combination? Check it in the Drug Interaction Checker →
Key Takeaways
- Interaction severity: Moderate
- Risk: Serotonin syndrome (agitation, hyperthermia, rigidity), excessive sedation.
- Mechanism: Risk of serotonin syndrome, especially with tramadol and tapentadol combined with SSRIs/SNRIs. Additive CNS depression with sedating antidepressants.
- Naproxen: S4 in Australia, low risk
- Amitriptyline: S4 in Australia, moderate risk
- Claims action: Monitor and document. Request clinical justification if combination is ongoing.
Naproxen vs Amitriptyline at a Glance
| Property | Naproxen | Amitriptyline |
|---|---|---|
| Brand names | Pediapharm Naproxen Suspension 25 mg/mL (Medexus Pharma, Canada), Proxen SR 750, Naprosyn SR750 | ENTRIP, Amitriptyline Lupin, APX-Amitriptyline |
| Drug class | opioid | antidepressant |
| Risk level | low | moderate |
| TGA Schedule (AU) | S4 | S4 |
Why Is This Combination Dangerous?
Risk of serotonin syndrome, especially with tramadol and tapentadol combined with SSRIs/SNRIs. Additive CNS depression with sedating antidepressants.
Regulatory Guidance by Jurisdiction
Australia TGA / SIRA / WorkSafe
The TGA and Australian Medicines Handbook classify this as a moderate drug interaction requiring monitoring and clinical review.
United Kingdom NICE / MHRA / FPM
NICE guidelines advise against combining multiple serotonergic medications due to the risk of serotonin syndrome. For personal injury claims, antidepressant prescribing should be reviewed for injury relatedness and appropriateness.
United States FDA / CDC / State WC
The FDA has issued Drug Safety Communications about the risk of serotonin syndrome with concurrent use of serotonergic medications. Workers compensation nurse case managers should flag this combination for prescriber review.
What Claims Professionals Should Do
- Document the combination in the claim file with a note on interaction risk
- Request clinical justification from the prescriber at the next review
- Monitor for adverse effects including excessive sedation, falls, and cognitive impairment
- Assess injury relatedness of both medications to the compensable condition
- Review at next claim assessment and consider whether the combination is still clinically appropriate
Clinical reference
A clinical summary of Naproxen and Amitriptyline drawn from regulator advisories, national guidelines, and authoritative drug references. Read this if you want the deeper clinical picture before talking to your prescriber or pharmacist.
Severity assessment
Major. The co-administration significantly increases the risk of serious gastrointestinal bleeding and ulceration.
Mechanism (plain English)
Amitriptyline, a tricyclic antidepressant, can affect how blood platelets work, making them less effective at forming clots. Naproxen, a non-steroidal anti-inflammatory drug (NSAID), also thins the blood slightly by inhibiting platelet aggregation and can irritate the lining of the stomach. When these two medications are taken together, their individual effects on bleeding risk are additive, leading to a substantially higher chance of developing stomach ulcers or internal bleeding in the digestive tract.
Evidence level
Regulator-flagged. The increased risk of gastrointestinal bleeding with NSAIDs is well-documented and highlighted in product information from regulatory bodies, and the antiplatelet effects of TCAs like amitriptyline are also recognized, leading to a combined increased risk. [1], [2], [3]
Top regulator advisories (cite verbatim or close paraphrase)
- TGA (Australia): No pair-specific public advisory found. Australian product information for NSAIDs generally advises caution regarding gastrointestinal bleeding, especially with concomitant use of other medications that increase bleeding risk. Similarly, product information for amitriptyline notes its potential to affect platelet function. [4], [5]
- MHRA / NICE (UK): No specific guidance found for this exact pair. However, the British National Formulary (BNF) and NICE guidelines for NSAIDs and antidepressants generally advise caution when co-prescribing medications that increase the risk of gastrointestinal bleeding. [6], [7]
- FDA / CDC (US): No specific safety communication found for this exact pair. FDA labels for NSAIDs carry prominent warnings about serious gastrointestinal adverse events, including bleeding and ulceration. Amitriptyline FDA labels also mention potential effects on blood components. [8], [9]
- EMA (Europe): No pair-specific public advisory found. European product information for both drug classes advises caution regarding bleeding risks when co-administered with other agents that increase this risk.
Clinical risk factors that elevate the danger
- Age: Patients over 65 years old are at a significantly higher risk of gastrointestinal bleeding. [1]
- History of gastrointestinal issues: Individuals with a history of stomach ulcers, gastrointestinal bleeding, or inflammatory bowel disease. [1]
- Concomitant medications: Use of other blood-thinning medications (e.g., anticoagulants like warfarin, antiplatelet agents like aspirin, or other SSRIs/SNRIs). [1]
- Alcohol consumption: Regular or heavy alcohol use increases the risk of stomach irritation and bleeding. [1]
- Smoking: Smoking is a known risk factor for gastrointestinal ulcers. [1]
- Cardiovascular disease: Patients with cardiovascular disease may be at increased risk due to the potential for NSAIDs to increase cardiovascular thrombotic events. [2]
What a patient should be told
- The risk: Taking amitriptyline and naproxen together can significantly increase your risk of serious stomach problems, including ulcers and internal bleeding. This can be very serious, even life-threatening.
- Warning signs: Be vigilant for signs of bleeding such as black, tarry stools, vomit that looks like coffee grounds, severe stomach pain, or unusual bruising. Seek immediate medical attention if you experience any of these.
- Do not stop suddenly: Do not stop taking either medication without first talking to your doctor or pharmacist, even if you experience side effects. They can help you manage your medications safely.
- Safer alternatives: Discuss with your doctor or pharmacist if there are alternative pain relief options or if a 'stomach protector' medication (like omeprazole) is needed to reduce your risk.
- Urgent care triggers: If you have severe stomach pain, persistent vomiting, or pass black or bloody stools, go to the nearest emergency department immediately.
Top 3 sources (with full citation)
- Can I take Amitriptyline and Naproxen together? Patient.info. Originally published 25 Jan 2026. https://patient.info/medication-interactions/amitriptyline-and-naproxen-bp-interaction
- Amitriptyline with Naproxen. Drugs.com. Date Unknown. https://www.drugs.com/drug-interactions/amitriptyline-with-naproxen-168-0-1690-0.html
- Amitriptyline Hydrochloride Tablets, USP Rx Only. U.S. Food and Drug Administration (FDA). Date Unknown. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/085968s112lbl.pdf
Notes for the reviewing pharmacist
While some drug interaction checkers may initially report no direct interaction between amitriptyline and naproxen, it is crucial to recognize the additive pharmacodynamic effects that significantly elevate the risk of gastrointestinal bleeding. Both agents contribute to impaired platelet function and NSAIDs directly irritate the gastric mucosa. The risk is particularly pronounced in elderly patients and those with a history of GI pathology. Prophylactic gastroprotective agents should be strongly considered for high-risk individuals. It is important to counsel patients thoroughly on warning signs and the necessity of not self-discontinuing medication. The evidence for this interaction is primarily derived from the known adverse effect profiles of each drug class and general guidelines for co-prescribing agents that increase bleeding risk, rather than specific studies on this exact combination. Therefore, a careful risk-benefit assessment is essential for each patient.
Check this medication against your full medication list
Check all interactions for Naproxen and Amitriptyline across your claimant's full medication list.
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.
Related Resources
Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.